1. Foxp3 expression in T regulatory cells and other cell lineages

   • Christel Devaud
   • Phillip K. Darcy
   • Michael H. Kershaw

   Review 26 July 2014 Pages: 869 - 876

2. Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2

   • Wei Xie
   • Daojuan Li
   • Min Wang

   Original Article 04 June 2014 Pages: 877 - 888

   

3. Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling

   • Thomas A. Mace
   • Samantha A. King
   • Gregory B. Lesinski

   Original Article 04 June 2014 Pages: 889 - 900

   

4. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

   • Francesca Pretto
   • Giuliano Elia
   • Dario Neri

   Original Article 04 June 2014 Pages: 901 - 910

   

5. Intrinsically de-sialylated CD103⁺ CD8 T cells mediate beneficial anti-glioma immune responses

   • Emmanuel Jouanneau
   • Keith L. Black
   • Christopher J. Wheeler

   Original Article 04 June 2014 Pages: 911 - 924

   

6. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity

   • Kea Martin
   • Philipp Müller
   • Alfred Zippelius

   Original Article 07 June 2014 Pages: 925 - 938

   

7. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer

   • Moon Jae Chung
   • Jeong Youp Park
   • Si Young Song

   Original Article 12 June 2014 Pages: 939 - 946

   

8. The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII^−/− mice

   • Michelle A. Sallin
   • Xiaoyu Zhang
   • Scott E. Strome

   Original Article 14 June 2014 Pages: 947 - 958

   

9. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula

   • Sandra Van Lint
   • Sofie Wilgenhof
   • Kris Thielemans

   Focussed Research Review 31 May 2014 Pages: 959 - 967

   

10. Engineered T cells for cancer therapy

    • Carl H. June
    • Marcela V. Maus
    • David L. Porter

    Focussed Research Review 19 June 2014 Pages: 969 - 975

    

11. Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy

    • Yago Pico de Coaña
    • Giuseppe Masucci
    • Rolf Kiessling

    Focussed Research Review 26 June 2014 Pages: 977 - 983

    

12. “Immunotherapy of cancer: present status and future promise”: Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd–25th September 2013

    • Marco Donia
    • Rikke Lyngaa
    • Sine Reker Hadrup

    Meeting Report Open access 24 July 2014 Pages: 985 - 989